AIM ImmunoTech

AIM ImmunoTech
AIM
AMEX: AIM
IndustryBiopharmaceutical
Headquarters
Ocala, Florida
,
USA
Key people
CEO Thomas K. Equels, J.D.
COO Peter W. Rodino III, J.D.
CFO Ellen Lintal
ProductsAmpligen
Alferon
ServicesCancer and immunotherapy research
Total assets$ 64.584 million  (2020)

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.

The company has created an immunomodulatory double stranded RNA drug called Ampligen.

It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.